Dear Fellow Shareholders of Nutra Pharma:

As the Chairman, Chief Executive Officer, and fellow investor in the Company, I am excited and pleased to share with you the recent progress we have made in our drug research.

Last week marked one of the most exciting accomplishments for our company. As many of you read in our press release; on Tuesday, our wholly-owned drug discovery subsidiary, ReceptoPharm, successfully completed its 15-month Phase IIb/IIIa clinical trial for the treatment of Adrenomyeloneuropathy (AMN).

As our first Phase II trial to be completed, this not only adds tremendous credibility to our research, but it also provides additional evidence supporting the safety and efficacy of our leading drug candidate for neurological and autoimmune disorders, RPI-78M.

Although data from the Trial is still being collected and analyzed, initial feedback from physicians involved in the trial was positive. We look forward to presenting our data by the end of September.

As part of our ongoing commitment to maintain a high level of transparency and communication with our shareholders and those interested in our company, we continue to post articles to the NPC Blog. We invite you to read our recent entries, which include in-depth commentaries about our work with Adrenomyeloneuropathy and Nontuberculous Mycobacteria. You can also opt-in to receive these posts through your email by filling out and submitting the “Blog Updates” form when you visit the blog at the above address.

In addition to the NPC Blog, we post our recent press announcements online. If you would like to receive the latest news from the Company, I invite you to subscribe to our “E-Alerts”. Just visit http://www.NutraPharma.com, fill out the “E-Alerts” form on the lower left column of the homepage and click “subscribe”. “E-Alerts” are separate from “Blog Updates”, so you will need to sign up for each individually if you would like to receive both company news and blog posts by email.

As always, if you have any additional questions or would like more information, please contact the Investor Relations Hotline at (877) 895-5647.

Sincerely yours,
Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation

Adrenomyeloneuropathy (AMN) is a rare hereditary disease that affects approximately 30,000 people worldwide. Even though most people have never heard of AMN, it continues to be a very important focus for Nutra Pharma’s drug development.

Our goal is to receive the approval to launch the first-ever treatment for AMN using our lead drug candidate for autoimmune and neurological disorders, RPI-78M. Almost a year and a half ago, we began a 15-month phase IIb/IIIa human clinical trial in London to help us better understand the efficacy of RPI-78M in treating AMN. Because patients started the trial at different times (we refer to this as a staggered start), the trial is now coming to a close.

One of the primary reasons we chose to focus on AMN is because its symptoms display very similar characteristics to those of Multiple Sclerosis (MS). Many who have followed Nutra Pharma over the years already know that we are researching a possible treatment for MS. Both AMN and MS are characterized by demyelination, or, the loss of the myelin sheath insulating the nerves.

Our previous clinical trial data has led us to believe that RPI-78M induces gamma-interferon and interleukin-27 (IL-27). Recently, IL-27 was discovered to be an important anti-inflammatory regulator in cells of the immune system and many scientists now believe that IL-27 helps reduce symptoms of MS. We feel this property is not isolated to MS, but extends into AMN as well.

As a side note, we filed a patent with the United States Patent office in April 2007 to protect our method of regulating IL-27 using modified cobratoxin.

Because we are just now completing our phase IIb/IIIa clinical trial for the treatment of AMN, we expect to have the data compiled by mid to late August. Once we finish reviewing this data, it will be released to the public and our shareholders.

In the meantime, here are some additional resources for learning more about Adrenomyeloneuropathy:

AMNhelp.com
An online resource published by Nutra Pharma about AMN

AMN Community on RareShare
An online community for people affected by AMN

United Leukodystrophy Foundation
A foundation dedicated to helping children and adults who have Leukodystrophy and assisting the family members, professionals and support services that serve them.